•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
argenx said it will present new clinical data for VYVGART at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026, covering myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company also plans updates across its neuromuscular pipeline, including Phase 3 programs evaluating empasiprubart in CIDP and follow-up data for adimanebart in congenital myasthenic syndromes (CMS).
argenx highlighted results from multiple Phase 3 studies designed to broaden VYVGART’s use across MG subtypes, including ocular MG (oMG) and generalized MG (gMG) regardless of antibody status.
The Phase 3 ADAPT OCULUS study evaluated VYVGART in adult patients with ocular MG (MGFA Class I). The company said the trial met its primary endpoint (p=0.012), with oMG patients treated with VYVGART showing statistically significant improvement from baseline in the Myasthenia Gravis Impairment Index (MGII) ocular scores at Week 4 versus placebo.
argenx added that improvements were supported by a combined patient-reported outcome and physician examination (PRO+PE) assessment (p=0.018), with consistent clinical improvement in ocular symptoms including diplopia (double vision) and ptosis (drooping of the upper eyelids). The company said the data are intended to support a supplemental Biologics License Application (sBLA) to expand the label into oMG.
In the Phase 3 ADAPT SERON trial, argenx reported that patients treated with VYVGART—across MuSK+, LRP4+, and triple seronegative generalized myasthenia gravis—experienced rapid improvements and increasingly pronounced efficacy with each additional cycle in an open-label extension.
The company cited improvements as measured by Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores. It said an sBLA for this patient population has been granted priority review by the U.S. Food and Drug Administration (FDA), with a target action date of May 10, 2026.
Results from ADAPT Jr were presented for adolescent participants aged 12-17. argenx said participants showed consistent and repeatable MG-ADL improvements across treatment cycles, with 72.7% achieving minimal symptom expression (MSE) in cycle one and 80% achieving MSE in cycle two. Enrollment of a younger pediatric cohort is ongoing.
For CIDP, argenx presented data intended to support earlier use of VYVGART Hytrulo and to characterize real-world switching from IVIg.
In an ADHERE post hoc analysis, argenx said 87.5% of treatment-naïve patients treated with VYVGART Hytrulo achieved confirmed early clinical improvement. The company reported a median time to response of 39.5 days, describing the findings as addressing an evidence gap in patients historically underrepresented in CIDP trials.
argenx also cited real-world physician insights from an assessment of 225 patients. The company said 85.7% of the 91 patients who attempted to switch from IVIg to VYVGART Hytrulo were successful, defined as clinical improvement or maintaining stability without tolerability issues.
It said switching was driven by clinical and practical considerations, including prior treatment dissatisfaction or lack of efficacy, IVIg-related safety or tolerability concerns, poor venous access, adherence challenges, and patient preference.
Beyond VYVGART, argenx said it will present additional neuromuscular pipeline data at AAN 2026.
The company said two Phase 3 CIDP studies will be presented for empasiprubart. These include EMVIGORATE, a head-to-head study versus IVIg, and EMNERGIZE, which evaluates empasiprubart versus placebo.
argenx reported follow-up results from a Phase 1b study of adimanebart, a MuSK agonist antibody, in DOK7 CMS. The company said improvements in key QMG components and six-minute walk test performance (total distance and cadence) observed during a 12-week treatment period were generally maintained throughout a 30-week treatment-free follow-up period.
Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx, said the company is working to expand VYVGART’s reach across MG subtypes and highlighted the potential for early clinical improvement in treatment-naïve CIDP patients.
Samantha Masterson, President and CEO of the Myasthenia Gravis Foundation of America, said MG research continues to advance treatment options across a broader range of MG patient populations and that progress is measured by fewer debilitating symptoms and more stable days.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
